

STEVE SISOLAK
Governor



RICHARD WHITLEY, MS
Director

SUZANNE BIERMAN, JD, MPH
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS COMMITTEE

AGENDA

Date of Publication: February 19, 2019

Date and Time of Meeting: March 28, 2019 at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: Springs Preserve
333 S. Valley View Blvd.
Las Vegas, Nevada 89107

Please check with staff to verify room location

Place of Meeting: Optum Office
9850 Double R Blvd., Suite 200
Reno, Nevada 89521

Webinar Registration: <https://optum.webex.com/optum/onstage/g.php?MTID=ee98bab98e724ebd24d73f77fbb74255b>

OR

www.webex.com, select "Join," enter Meeting Number 644 842 292, your name and email and then select, "Join."

A Password should not be necessary, but if asked, enter "jEAtDb3@"

OR

Audio Only: (763) 957-6300

Event Number: 644 842 292

Follow the instructions that appear on your screen to join the teleconference. Audio will also be broadcast over the internet (VoIP).

Items may be taken out of order.
Items may be combined for consideration by the public body.
Items may be pulled or removed from the agenda at any time.

Public comment is limited to five minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

1. Call to Order and Roll Call

2. Public Comment

3. Administrative

- a. **For Possible Action:** Review and Approve Meeting Minutes from November 15, 2018
- b. Status Update by the DHCFP
 - 1. Public Comment

4. Proposed New Drug Classes

- a. Anti-migraine Agents – Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists
 - 1. Public Comment
 - 2. Drug Class Review Presentation – OptumRx
 - 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the DHCFP
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Toxicology Agents – Substance Abuse Agents – Withdrawal Agents

1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- c. Toxicology Agents – Substance Abuse Agents – Opiate Antagonist Extended Release Injections
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
5. **Established Drug Classes Being Reviewed Due to the Release of New Drugs**
- a. Anti-infective Agents – Antivirals – Influenza Agents
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Autonomic Agents – Sympathomimetics – Self-injectable Epinephrine
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action

- a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- c. Hormones and Hormone Modifiers – Androgens
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- d. Ophthalmic Agents – Antiglaucoma Agents
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- e. Ophthalmic Agents – Ophthalmics for Dry Eye Disease
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

6. Established Drug Classes

- a. Toxicology Agents – Substance Abuse Agents – Mixed Opiate Agonists/Antagonists (Oral)
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Analgesics – Analgesic/Miscellaneous – Neuropathic Pain/Fibromyalgia Agents
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- c. Anti-infective Agents – Antivirals – Anti-hepatitis Agents – Polymerase Inhibitors/Combination Products
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- d. Dermatological Agents – Topical Anti-Infectives – Topical Antifungals (Onychomycosis)

1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
7. **Report by OptumRx on New Drugs to Market, New Generic Drugs to Market and New Line Extensions**
8. **Closing Discussion**
- a. Public comments on any subject
 - b. Date and location of the next meeting
 - c. Adjournment

Items may be taken out of order. Two or more agenda items may be combined for consideration. Items may be removed from the agenda or discussion of items may be delayed at any time.

Notice of this public workshop meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site at <http://dhcftp.nv.gov>. The agenda posting of this meeting can be viewed at the follow locations: Carson City Central Office; Las Vegas District Office; Reno District Office; Elko District Office; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Esmeralda County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the proposal will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 101, Carson City, Nevada 89701 at least three days prior the public workshop.

All persons that have requested in writing to receive the Public Workshop Agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public who are physically challenged and wish to attend the meeting. If special arrangements for the meeting are necessary, please notify the DHCFP, in writing, at 1100 East William Street, Suite 101, Carson City, or call Tanya Benitez at (775) 684-3730, as soon as possible, or e-mail at tbenitez@dhcftp.nv.gov.
